

<b>Öffentlicher Titel</b>	Phase-II-Studie zu Ruxolitinib-Behandlung versus allogene Stammzelltransplantation bei Patienten mit Myelofibrose
<b>Wissenschaftl. Titel</b>	Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study)
<b>Kurztitel</b>	RuxoAllo
<b>Studiennummer KN/ELN</b>	LN_GSGMPN_2015_635
<b>Studiengruppe</b>	GSG-MPN
<b>Studienart</b>	multizentrisch
<b>Studienphase</b>	Phase II
<b>Erkrankung</b>	Myeloproliferative Neoplasien (MPN) - Myelofibrose
<b>Leukämiestadium</b>	.
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"> <li>- Symptomatic primary myelofibrosis or myelofibrosis post polycythaemia vera or essential thrombocythemia stage intermediate 2- or high-risk according to IPSS or DIPSS [46] or inter-mediate 1-risk with high risk cytogenetics, other than normal karyotype, sole del 20q, del 13q, or sole +9, or transfusion-dependency</li> <li>- Patients age: 18 - 70 years at time of inclusion (female and male)</li> <li>- Patients understand and voluntarily sign an informed consent form</li> <li>- Platelet count 50 x 10<sup>9</sup>/L</li> <li>- No prior Ruxolitinib treatment</li> <li>- ECOG 2</li> </ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"> <li>- Severe renal, hepatic, pulmonary or cardiac disease, such as: • Total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level • Left ventricular ejection fraction &lt; 30 % • Creatinine clearance &lt; 30 ml/min • DLCO &lt; 35 % and/or receiving supplementary continuous oxygen</li> <li>- Positive serology for HIV</li> <li>- Pregnant or lactating women (positive serum pregnancy test)</li> <li>- Age &lt; 18 and 71 years.</li> <li>- Uncontrolled invasive fungal infection at time of screening (baseline)</li> <li>- Serious psychiatric or psychological disorders</li> <li>- Participation in another study with ongoing use of unlicensed investigational product from 28 days before study enrollment</li> <li>- Transformation to AML</li> </ul>
<b>Alter</b>	18 - 70 Jahre
<b>Status</b>	Aktiv
<b>Beginn der Rekrutierung</b>	23.12.2015
<b>Fallzahl</b>	155
<b>Studienleiter/in</b>	Kröger, Prof. Dr. med., Nicolaus Universitätsklinikum Hamburg Knochenmartransplantation Martinistrasse 52 20246 Hamburg Tel: +49 (0)40 42803 5864 Fax: +49 (0)40 42803 3795 E-Mail: <a href="mailto:nkroeger@uke.uni-hamburg.de">nkroeger@uke.uni-hamburg.de</a>